Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer
In Partnership With:
Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.
Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.
Targeting dual anti-HER2 targeting therapy is attractive, says Freedman, especially ONT-380, which does not have as many adverse events as seen with therapies such as neratinib (Nerlynx).
